Luis Ortega-Paz

Luis Ortega-Paz interviews Deepak L. Bhatt about the results of the Phase 3 Reverse-it trial which he presented during the ACC.25 in Chicago.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Luis Ortega provides his take on the SEISMIC-HF I study presented by Liviu Klein at AHA 2024, in Chicago.

Stay up to date with what is new and hot in interventional cardiology at #AHA24 in Chicago.

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

What was new and hot in interventional cardiology at #ESCCongress 2024!

Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.

ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24

Luis Ortega Paz provides his take on DAPA-MI - A registry-based randomized trial of dapagliflozin in patient with acute myocardial infarction without diabetes, which was presented by Stefan James at AHA 2023 in Philadelphia.

Luis Ortega Paz interviews Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA 2023 Congress in Philadelphia.

Stay up to date with what is new and hot in interventional cardiology at #AHA23 in Philadelphia.

Luis Ortega-Paz interviews Josep Rodés-Cabau on the results of the VIVA trial which he presented at TCT Congress 2023 in San Francisco.

Thanks to the contribution of our team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science to be released at TCT 2023 - check out the list here!

What was new and hot in interventional cardiology at #ESCCongress 2023!

Luis Ortega-Paz interviews Simone Biscaglia and Gianluca Campo about the FIRE trial.
Results showed elderly patients presenting with either STEMI or NSTEMI benefit from complete revascularization, reducing cardiovascular events risk at 1 year compared to culprit lesion-only PCI.

Published simultaneously in the New England Journal of Medicine

Luis Ortega Paz interviews Prof. Sanjit Jolly who presented the prespecified analysis of the randomised UNIVERSAL trial at the CRT meeting which was held on February 25-28, 2023 in Washington, DC, USA.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology / World Heart Federation 2023 Scientific Sessions #ACC23 #WCCardio.

Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2022 - check out the list here!

Watch Luis Ortega Paz's interview with David Berg as part of the ESC 2022 Congress coverage, and find out more about the COVID-PACT trial, which aims to study antithrombotic strategies in critically ill COVID-19 patients. Learn more about the study design (population, primary endpoint, safety criteria...)...

Stay up to date with what was new and hot in interventional cardiology at the #ESCCongress 2022!

Luis Ortega Paz interviews Pascal Vranckx on the background, main results and take-home messages from the sub-analysis of the MASTER DAPT study.

Watch this EuroPCR 2022 session if you want to know the latest updates on integrating physiology into optimal revascularization in the cathlab: improvements in wire-based technologies, QFR from online or offline CAG, CT angio coupled with FFR, and physiology-guided vs angio-guided revascularization in ACS.

Luis Ortega-Paz interviews Frederik Zimmermann, first co-author of the FAME 3 Trial which he presented during the American College of Cardiology’s annual scientific sessions. The trial was published simultaneously in the journal Circulation.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2022 Scientific Sessions #ACC22.

TCT 2021: Luis Ortega Paz interviews Rafael Romaguera, principal investigator of the SUGAR trial. SUGAR is the first powered trial to compare new generation DES in patients with diabetes, and also the first to include a broad population of patients with diabetes (all-comers design). It was...

Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2021 - check out the list here!

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

ESC Congress 2021: Discover the interview given by Marco Valgimigli to Luis G. Ortega-Paz for PCRonline about the MASTER-DAPT trial to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events.

Make sure you stay up to date with what's new and hot in interventional cardiology at this year's #ESCCongress!